Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative outcomes of intra-aortic balloon pump versus impella in non-myocardial infarction cardiogenic shock: A National Inpatient Sample Database analysis.

JHLT open·2026
Same author

Biventricular impella support in acute antibody-mediated cardiac allograft rejection with severe hemodynamic compromise.

Journal of cardiothoracic surgery·2026
Same author

Social Determinants of Health and Outcomes in Transthyretin Amyloid Cardiomyopathy.

The American journal of cardiology·2026
Same author

Identification of Heart Transplant Rejection Subtypes With Circulating MicroRNAs.

Circulation. Heart failure·2026
Same author

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.

Future cardiology·2025
Same author

Left Atrial Dysfunction in Patients with Atrial Fibrillation and Heart Failure.

Current cardiology reports·2025
Same journal

Providers' Perspectives on Hospital-Based Tobacco Treatment Efforts.

The American journal of the medical sciences·2026
Same journal

In Memoriam: Maurice A. Mufson, MD, MACP.

The American journal of the medical sciences·2026
Same journal

Outcomes of acute myeloid leukemia patients admitted to the intensive care unit within 100 days of allogeneic hematopoietic stem cell transplantation.

The American journal of the medical sciences·2026
Same journal

Association Between Reverse Triiodothyronine and Cardiac Complications in Patients with Uncontrolled Graves' Disease.

The American journal of the medical sciences·2026
Same journal

Chlorthalidone vs. hydrochlorothiazide in hypertension management: Lessons for guiding clinical practice.

The American journal of the medical sciences·2026
Same journal

The impact of COVID-19 on alcohol-associated hepatitis and alcohol-associated cirrhosis.

The American journal of the medical sciences·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Right ventricular dysfunction: lessons learned from mechanical circulatory assist devices.

Michael L Hess1, Richard H Cooke, Amit Varma

  • 1Virginia Commonwealth University Health System; VCU Pauley Heart Center, Division of Cardiovascular Medicine, Advanced Heart Failure and Transplantation, Richmond, Virginia.

The American Journal of the Medical Sciences
|February 22, 2013
PubMed
Summary
This summary is machine-generated.

Right heart failure significantly contributes to advanced left heart failure progression. Understanding right ventricular dysfunction is crucial for managing heart failure and selecting appropriate mechanical circulatory support devices.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Experiment Videos

Last Updated: May 14, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Area of Science:

  • Cardiology
  • Medical Devices
  • Heart Failure Research

Background:

  • Congestive heart failure (CHF) affects millions annually, with advanced stages (New York Heart Association class III-IV) showing inexorable deterioration.
  • Current treatments like pharmacotherapy, automated implantable cardioverter defibrillators (AICDs), and cardiac resynchronization therapy (CRT) offer limited long-term solutions for severe CHF.
  • The scarcity of heart transplant donors necessitates alternative advanced therapies for end-stage heart failure.

Purpose of the Study:

  • To investigate the role of right heart failure as a major contributor to the progression of New York Heart Association class IV left heart failure.
  • To identify key predictors of right ventricular dysfunction in patients with advanced heart failure.
  • To compare the insights gained from left ventricular assist devices (LVADs) and total artificial hearts (TAHs) regarding the significance of right ventricular function.

Main Methods:

  • Review and analysis of clinical data and outcomes related to patients with advanced heart failure.
  • Comparative analysis of device performance and patient selection criteria for LVADs and TAHs.
  • Identification and evaluation of prognostic indicators for right ventricular dysfunction.

Main Results:

  • Right ventricular dysfunction is a significant factor in the progression of advanced left heart failure.
  • Specific predictors of right ventricular dysfunction were identified, informing clinical decision-making.
  • The study highlights the critical role of right ventricular function in the pathophysiology of heart failure and device selection.

Conclusions:

  • Right heart failure is a key driver of poor outcomes in advanced left heart failure.
  • Accurate assessment of right ventricular function is essential for successful LVAD implantation and management.
  • Total artificial hearts may be considered for patients with severe biventricular failure where LVADs are contraindicated due to right heart dysfunction.